About Index Trending news
Analyze
Pricing
Novartis Venture Fund

Novartis Venture Fund

Novartis Venture Fund

Elsewhere

Alexa global traffic share

Investment profile

Target markets
Health Care Biotechnology Health Diagnostics

Activity

Past year's investments

- Novartis Venture Fund participated in 9 rounds in the past year.
- The total disclosed amount of capital deployed in those rounds was $292,982,051 (averaging $32,553,561 per round).

Latest rounds

- Effector Therapeutics: Venture capital (Series C) ($38.6M)
- NeuroVia: Venture capital (Series A) ($14M)
- Neurovia: Venture capital (Series A) ($14M)

Main Co-investors

- Morgenthaler Ventures
- Consort Medical
- SR One

Total funding
$102.1M in 6 rounds from 13 investors
By Novartis Venture Fund
$53M Series C in Nov, 2014
Total funding
$110.4M in 4 rounds from 25 investors
By Novartis Venture Fund
$35M Series D in Jan, 2017
Total funding
$30.7M in 2 rounds from 5 investors
By Novartis Venture Fund
$16M Venture capital in Feb, 2015
Total funding
$28M in 1 rounds from 5 investors
By Novartis Venture Fund
$28M Series A in Feb, 2015
Total funding
$43.7M in 3 rounds from 11 investors
By Novartis Venture Fund
$30.2M Series B in Nov, 2009
Total funding
$41.8M in 6 rounds from 13 investors
By Novartis Venture Fund
$16M Series B in Aug, 2014
Total funding
$73.6M in 2 rounds from 6 investors
By Novartis Venture Fund
$70.6M Series A in Aug, 2008
Total funding
$49M in 2 rounds from 7 investors
By Novartis Venture Fund
$41M Series B in Apr, 2014
Total funding
$137.2M in 4 rounds from 15 investors
By Novartis Venture Fund
$54.8M Series C in May, 2009
Total funding
$96.7M in 6 rounds from 26 investors
By Novartis Venture Fund
$5.1M Venture capital in Apr, 2013
Total funding
$83.6M in 2 rounds from 19 investors
By Novartis Venture Fund
$38.6M Series C in Jul, 2017
Total funding
$61.1M in 3 rounds from 21 investors
By Novartis Venture Fund
$41M Series C in Jun, 2013
Total funding
$10M in 1 rounds from 4 investors
By Novartis Venture Fund
$10M Series B in Feb, 2007
Total funding
$40M in 1 rounds from 7 investors
By Novartis Venture Fund
$40M Series D in May, 2009
Exit Abbott, Sep 3, 2009
Total funding
$13.2M in 1 rounds from 4 investors
By Novartis Venture Fund
$13.2M Series A in Mar, 2010
Exit Altimmune, Feb 17, 2015
Total funding
$27.7M in 3 rounds from 5 investors
By Novartis Venture Fund
$11M Series B in Mar, 2011
Total funding
$46.8M in 4 rounds from 13 investors
By Novartis Venture Fund
$21M Series B in May, 2014
Total funding
$46M in 2 rounds from 6 investors
By Novartis Venture Fund
$40M Series E in Sep, 2016
Total funding
$29.5M in 2 rounds from 4 investors
By Novartis Venture Fund
$25.5M Series B in Dec, 2009
Total funding
$17M in 1 rounds from 3 investors
By Novartis Venture Fund
$17M Series A in Oct, 2014
Total funding
$331.4M in 4 rounds from 9 investors
By Novartis Venture Fund
$40M Undisclosed in Mar, 2017
Total funding
$51M in 1 rounds from 3 investors
By Novartis Venture Fund
$51M Series A in Jan, 2016
Total funding
$60M in 1 rounds from 8 investors
By Novartis Venture Fund
$60M Venture Capital in Jun, 2016
Total funding
$44M in 1 rounds from 5 investors
By Novartis Venture Fund
$44M Series B in Jun, 2016
Total funding
$12.7M in 2 rounds from 8 investors
By Novartis Venture Fund
$11M Series A in May, 2017
Total funding
$31.1M in 3 rounds from 5 investors
By Novartis Venture Fund
$26.1M Series A in Jan, 2017
Total funding
$89.3M in 3 rounds from 9 investors
By Novartis Venture Fund
£40M Series B in Jun, 2017
Total funding
$14M in 1 rounds from 4 investors
By Novartis Venture Fund
$14M Series A in Jul, 2017
Total funding
$63M in 1 rounds from 6 investors
By Novartis Venture Fund
$63M Series A in Jul, 2017
Total funding
$14M in 1 rounds from 4 investors
By Novartis Venture Fund
$14M Series A in Jul, 2017

Want to see the complete list?
Go Pro!